lifestyle.californiaconsumerbanking.com

Author: Aspire Biopharma Holdings, Inc.

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

March 10, 2026
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

March 10, 2026
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

March 9, 2026
Aspire Biopharma’s Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

March 9, 2026
Aspire Biopharma’s Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

February 3, 2026
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

January 29, 2026
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

January 27, 2026
Aspire Biopharma’s Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

January 26, 2026
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

January 22, 2026
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

January 20, 2026